Research Updates

Researchers hope that by studying other neurodegenerative diseases, we can identify common causes that will help us develop new treatments for glaucoma.

Eye drops that reduce elevated pressure inside the eye can delay or possibly prevent the onset of glaucoma in African Americans at higher risk for developing the disease, researchers have found.

These videos with the Catalyst for a Cure researchers were filmed during a roundtable interview discussion in January 2011 at the Palace Hotel in San Francisco.

The Catalyst For a Cure has reshaped the direction of glaucoma research by taking a pioneering approach that should become a model for research in other diseases.

The research team identified a period of vulnerability for retinal ganglion cells early in the disease, when these cells are more sensitive to metabolic insults and stressors.

During the year 2009, the investigators of the Catalyst for a Cure (CFC1) consortium worked together to probe how retinal ganglion cells are damaged and decline in glaucoma.

In a recent study, David Calkins, PhD discovered that the first sign of injury in glaucoma actually occurs in the brain.

The Catalyst For a Cure (CFC1) researchers are: David Calkins, PhD, Philip Horner, PhD, Nicholas Marsh-Armstrong, PhD, and Monica Vetter, PhD.